REQUEST – FCF LIFE SCIENCE RESEARCH SERIES

FCF engages in research on recent financing trends in the Life Science sector, i.e. biotechnology, pharma and med-tech. FCF primarily focuses on the latest activities in the equity capital markets: Venture Capital, Initial Public Offerings (IPO) and Equity Valuations.

The findings are regularly published in

Bitte füllen Sie das Pflichtfeld aus.

Salutation

Bitte füllen Sie das Pflichtfeld aus.

Titel

Like Dr., Prof. ...

Bitte füllen Sie das Pflichtfeld aus.

First name

Bitte füllen Sie das Pflichtfeld aus.

Last name

Bitte füllen Sie das Pflichtfeld aus.

E-Mail

Bitte füllen Sie das Pflichtfeld aus.

Position

Bitte füllen Sie das Pflichtfeld aus.

Company

Consent to be contacted

FCF Fox Corporate Finance GmbH (FCF) uses the information in this form to stay in touch with you and to inform you about events and latest market analyses.

Please fill mandatory field

Yes, I agree to be contacted by FCF.*

Bitte füllen Sie das Pflichtfeld aus.

Yes, I agree that FCF can contact me via E-Mail for the purposes of data maintenance.

I agree that for the stated purposes my data will be electronically processed by FCF. I can revoke this consent at any moment in time - without reasoning - and cancel the receipt of the FCF News with immediate effect. FCF will treat my data confidentially and will not disclose it to third parties.

Please fill mandatory field

Yes, I agree with the data protection provisions of FCF.

Learn more about our privacy policy.
* Mandatory fields

** All information and market analyses published by FCF are exclusively directed to and for the use by current and potential institutional clients, partners and investors. FCF retains the right to reject your request. To verify your request, we therefore need qualified details for the required fields.

CureVac – ein Weckruf für deutsche Investoren

Dass die Corona-Krise besondere Entwicklungen mit sich bringt, ist in vielen Bereichen zu spüren. Die Auswirkungen der Ausbreitung des Virus sind in dieser Form noch nie dagewesen. Die deutsche CureVac könnte ein Weckruf für die

March 27, 2020

A gap with causes | Going Public 03/2020

German life science companies must raise more money abroad The fact that Germany’s life science industry is doing very well in European comparison is due to a few big deals. The latest venture capital research

March 25, 2020

thumbnail of Cover-FCF-Life-Science-VC-Monitor-02-2020

FCF Life Science Venture Capital Monitor – 02/2020 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Science Venture Capital Monitor – 02/2020”. The Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies,

March 11, 2020

FCF Life Science Venture Capital Monitor – 01/2020 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Science Venture Capital Monitor – 01/2020”. The Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies,

February 19, 2020

4th FCF Life Science Venture Capital Report published

The “4th FCF Life Science Venture Capital Report” addresses recent financing trends in the Life Science industry, investigating subsector activity, deal characteristics, cross-border and investor engagements in Europe and the US. Key insights were: Europe

February 17, 2020

Enno Spillner is joining the Life Science Advisory Board of FCF Fox Corporate Finance GmbH

Munich, 12. December 2019 (fcf) –Enno Spillner is joining the Life Science Advisory Board of FCF Fox Corporate Finance GmbH. The Munich-based finance specialist has gained a further renowned expert for its Life Science Advisory

December 12, 2019